Delivery Order SPE2DB22D1106-SPE2DB24FDVP2

Award Date 1/17/24
Potential Completion Date 1/18/24
Potential Value $37K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $41,873.67, is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract is a Delivery Order with a Firm Fixed Price pricing type and has an ultimate completion date of February 26, 2025. The award is part of a larger Indefinite Delivery Contract (IDC) that...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $9,647.22, is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML, a medical vaccine product. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,904.80, is a delivery order for the supply of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract has a firm fixed price pricing type and an ultimate completion date of July 18, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This is a federal contract award by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract has an award value of $8,653.34 and is for the supply of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccines. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $37,452.40, is for the delivery of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The contract has an ultimate completion date of June 25, 2024 and is a Firm Fixed Price Delivery Order. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a Delivery Order contract with a firm fixed price of $1,141.57 and a ceiling value of $1,141.57. The contract covers the provision of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product, with a performance period through November 13, 2024. The award does not have a set-aside designation, indicating open...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,964.50 firm-fixed-price delivery order is for the procurement of TYPHIM VI 25 MCG/0.5 ML VIAL 10ML, a vaccine product. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,795.34 firm fixed price delivery order is for the supply of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML, a vaccine product. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML, a vaccine product, with a ceiling value of $7,611.01. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, covering a comprehensive...
This federal contract award, valued at $7,533.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the procurement of 4,567,335,814 units of the TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccine. The award is a delivery order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
  • SPE2DB22D1106
    Indefinite Delivery Contract
  • SPE2DB22D1106-SPE2DB24FDVP2
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $37,451.30, is a delivery order for the TYPHIM VI 25 MCG/0.5 ML SYRNG 0.5ML vaccine. This award is part of a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This particular award does not have a set-aside designation, indicating open competition. The contract is a firm fixed-price agreement, with a performance period ending on January 18, 2024.

Generated 5/13/25, 10:12 AM